{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06489028",
            "orgStudyIdInfo": {
                "id": "allo-APZ2-CVU-III"
            },
            "organization": {
                "fullName": "RHEACELL GmbH & Co. KG",
                "class": "INDUSTRY"
            },
            "briefTitle": "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)",
            "officialTitle": "A Pivotal, Randomized, Placebo-controlled, Double-blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "allogeneic-positive-dermal-mesenchymal-stromal-cells-for-treatment-of-therapy-resistant-cvu-phase-iii"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-25",
            "studyFirstSubmitQcDate": "2024-07-02",
            "studyFirstPostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "RHEACELL GmbH & Co. KG",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "FGK Clinical Research GmbH",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Venous Leg Ulcer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Verum",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: allo-APZ2-CVU"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "allo-APZ2-CVU",
                    "description": "Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)",
                    "armGroupLabels": [
                        "Verum"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Complete wound closure",
                    "description": "Complete wound closure already persisting for at least two weeks",
                    "timeFrame": "18 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Complete wound closures at each post-baseline follow-up visit",
                    "description": "Complete wound closures at each post-baseline follow-up visit",
                    "timeFrame": "at each post-baseline follow-up visit (starting the day after intervention until month 16)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients at least 18 years old;\n2. Chronic venous leg ulcer at lower leg and/or ankle region that has not been present longer than 15 years, diagnosed by Doppler or Duplex sonography, ankle brachial index, physical examination and dermatological review;\n3. Wound size at V1 and V2 between 1 and 25 cm2 as measured by standardized photography;\n4. If patients have 2 or more ulcers at the same extremity, the target ulcer has to be separated from the other ulcers with a bridge of epithelialized skin at least 1 cm wide;\n5. Body mass index between 15 and 50 kg/m\u00b2;\n6. Patients able to understand the nature of the study and able to provide written informed consent prior to any clinical trial procedures;\n7. Women of childbearing potential must have a negative urine pregnancy test at Visit 1;\n8. Women of childbearing potential and their male partners must be willing to use highly effective contraceptive methods during the course of the clinical trial.\n\nExclusion Criteria:\n\n1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;\n2. Uncontrolled Diabetes mellitus i.e. Hemoglobin A1c (HbA1c) \\>9.0%;\n3. Peripheral Artery Disease including claudication with need of treatment or intervention;\n4. Acute deep vein thrombosis diagnosed within 30 days before V1, or untreated deep vein thrombosis;\n5. Wounds showing size reduction of more than 40% at Visit 2 compared to Visit 1;\n6. Patients unable or unwilling to tolerate leg ulcer compression system;\n7. Acute wound infection of ulcer requiring treatment as judged clinically;\n8. Current use of medications that are known to influence wound healing i.e. systemic immunosuppressives, cytotoxic medicinal products, systemic steroids (above Cushing-threshold level) at investigator\u00b4s discretion;\n9. Patients who, in the opinion of the investigator, for any reason are unable or unwilling to complete the trial per protocol (e.g. alcohol or substance abuse, not mobile, short life expectancy) or there is an evidence of any other medical condition (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;\n10. Any malignancy within the past 5 years, excluding successfully treated carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin without evidence of metastases;\n11. Pregnant or lactating women;\n12. Any known allergies to components of the IMP",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anna Moessmer",
                    "role": "CONTACT",
                    "phone": "004962217183380",
                    "email": "anna.moessmer@rheacell.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Anna Moessmer",
                    "affiliation": "RHEACELL GmbH & Co. KG",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Austria"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Czechia"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "France"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Germany"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Hungary"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Italy"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Netherlands"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Poland"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Slovakia"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "Sweden"
                },
                {
                    "facility": "RHEACELL Clinical Trial Site",
                    "city": "Multiple Locations",
                    "country": "United Kingdom"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014647",
                    "term": "Varicose Ulcer"
                },
                {
                    "id": "D000007871",
                    "term": "Leg Ulcer"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012883",
                    "term": "Skin Ulcer"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000014648",
                    "term": "Varicose Veins"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17395",
                    "name": "Varicose Ulcer",
                    "asFound": "Venous Leg Ulcers",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10883",
                    "name": "Leg Ulcer",
                    "asFound": "Leg Ulcers",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17206",
                    "name": "Ulcer",
                    "relevance": "LOW"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M15686",
                    "name": "Skin Ulcer",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17396",
                    "name": "Varicose Veins",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}